A new trading day began on Monday, with Autolus Therapeutics plc ADR (NASDAQ: AUTL) stock price down -3.30% from the previous day of trading, before settling in for the closing price of $2.12. AUTL’s price has ranged from $1.11 to $5.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -4.39%. With a float of $240.33 million, this company’s outstanding shares have now reached $266.14 million.
Considering the fact that the conglomerate employs 647 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -272.13%, operating margin of -2973.1%, and the pretax margin is -2600.97%.
Autolus Therapeutics plc ADR (AUTL) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Autolus Therapeutics plc ADR is 9.70%, while institutional ownership is 54.13%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -4.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.72% during the next five years compared to 21.36% growth over the previous five years of trading.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Here are Autolus Therapeutics plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 60.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.89, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Compared to the last year’s volume of 1.8 million, its volume of 2.5 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 35.83%. Additionally, its Average True Range was 0.15.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 71.32%, which indicates a significant increase from 57.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.71% in the past 14 days, which was lower than the 86.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.56, while its 200-day Moving Average is $2.55. Nevertheless, the first resistance level for the watch stands at $2.13 in the near term. At $2.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.28. If the price goes on to break the first support level at $1.98, it is likely to go to the next support level at $1.92. Should the price break the second support level, the third support level stands at $1.83.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
With a market capitalization of 545.59 million, the company has a total of 266,141K Shares Outstanding. Currently, annual sales are 10,120 K while annual income is -220,660 K. The company’s previous quarter sales were 8,980 K while its latest quarter income was -70,160 K.
